RNA sequencing data of 142 samples from 142 patients with HER2+ breast cancer treated with letrozole or tamoxifen (SOLTI PAMELA trial)

PAMELA (NCT01973660) is a non-randomized, open-label, multicentric, prospective translational research study in stage I-IIIA HER2+ breast cancer designed to evaluate the ability of the PAM50 intrinsic subtypes to predict pCR in the breast (pCRB) following 18 weeks of neoadjuvant lapatinib and trastuzumab (+/- hormonal therapy if hormone receptor [HR] positive). Patients with HR+ disease received letrozole (if postmenopausal) or tamoxifen (if pre-menopausal). The primary objective was to compare the pCRB rates of the HER2-E versus the non-HER2-E subtypes in the intent-to-treat population.EGA study EGAS00001006410

PAMELA（临床试验登记号NCT01973660）是一项针对Ⅰ~ⅢA期人表皮生长因子受体2阳性（HER2+）乳腺癌的非随机、开放标签、多中心前瞻性转化研究，旨在评估PAM50固有亚型在18周新辅助拉帕替尼联合曲妥珠单抗（激素受体[HR]阳性患者可联合或不联合内分泌治疗）治疗后，预测乳腺病理完全缓解（pCRB）的能力。其中，激素受体阳性患者将根据绝经状态接受来曲唑（绝经后患者）或他莫昔芬（绝经前患者）治疗。本研究的主要研究目标为在意向治疗人群中，比较HER2-E亚型与非HER2-E亚型的乳腺病理完全缓解率。本研究隶属于EGA研究EGAS00001006410。